A Bioequivalence Study of the 90-mg Daclatasvir Tablet Relative to the 3 × 30-mg Daclatasvir Phase 3 Tablets, and Relative Bioavailability Studies of Chewable Pediatric Tablets of Daclatasvir and Asunaprevir in Healthy Adult Subjects
Latest Information Update: 26 Feb 2015
At a glance
- Drugs Asunaprevir (Primary) ; Asunaprevir (Primary) ; Daclatasvir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 23 Feb 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Dec 2014 New trial record